
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7794646/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	8.2	388
2	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discovery, 2018, 8, 1142-1155.	9.4	138
3	Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11300-11305.	7.1	132
4	Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial. European Journal of Cancer, 2016, 59, 142-151.	2.8	124
5	The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. European Urology Focus, 2019, 5, 958-969.	3.1	86
6	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 91-100.	0.8	67
7	Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 367-375.	0.8	65
8	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Annals of Surgical Oncology, 2016, 23, 218-224.	1.5	61
9	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology, 2020, 3, 728-738.	5.4	61
10	Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC) Journal of Clinical Oncology, 2020, 38, 614-614.	1.6	55
11	Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy, 2017, 66, 281-298.	4.2	54
12	PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
13	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1306-1316.	0.8	41
14	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology, 2020, 5, .	11.9	39
15	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1135-1142.	0.8	36
16	Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients Journal of Clinical Oncology, 2019, 37, 645-645.	1.6	36
17	Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunology, Immunotherapy, 2012, 61, 2227-2238.	4.2	33
18	Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer Biology and Therapy, 2014, 15, 699-706.	3.4	32

#	Article	IF	CITATIONS
19	A deep learning-based framework for segmenting invisible clinical target volumes with estimated uncertainties for post-operative prostate cancer radiotherapy. Medical Image Analysis, 2021, 72, 102101.	11.6	32
20	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncolmmunology, 2018, 7, e1440168.	4.6	31
21	Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Seminars in Radiation Oncology, 2020, 30, 129-138.	2.2	27
22	Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer. European Urology Oncology, 2022, 5, 216-224.	5.4	26
23	Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biology and Therapy, 2015, 16, 657-661.	3.4	25
24	Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e273-e280.	1.9	25
25	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. , 2020, 8, e001198.		24
26	PSA-Net: Deep learning–based physician style–aware segmentation network for postoperative prostate cancer clinical target volumes. Artificial Intelligence in Medicine, 2021, 121, 102195.	6.5	24
27	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clinical Cancer Research, 2021, 27, 3818-3824.	7.0	21
28	Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clinical Genitourinary Cancer, 2019, 17, e263-e272.	1.9	19
29	A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 101-109.	0.8	19
30	Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 166.e9-166.e13.	1.6	17
31	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer, 2018, 16, e1221-e1235.	1.9	14
32	Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1387-1395.	0.8	14
33	Hydrogel Spacer Rectal Wall Infiltration Associated With Severe Rectal Injury and Related Complications After Dose Intensified Prostate Cancer Stereotactic Ablative Radiation Therapy. Advances in Radiation Oncology, 2021, 6, 100713.	1.2	14
34	Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma. Metabolites, 2021, 11, 608.	2.9	13
35	SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 290-301.	0.8	13
36	Natural history of â€~second' biochemical failure after salvage radiation therapy for prostate cancer: a multiâ€institution study. BJU International, 2018, 121, 365-372.	2.5	12

#	Article	IF	CITATIONS
37	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 6716-6725.	7.0	12
38	Anatomical patterns of recurrence following biochemical relapse after postâ€prostatectomy salvage radiation therapy: a multiâ€institutional study. BJU International, 2017, 120, 351-357.	2.5	10
39	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e1-790.e7.	1.6	10
40	Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521 Journal of Clinical Oncology, 2020, 38, 333-333.	1.6	10
41	Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. Practical Radiation Oncology, 2014, 4, 409-414.	2.1	7
42	Pretreatment biopsy analysis of DAB 2 IP identifies subpopulation of highâ€risk prostate cancer patients with worse survival following radiation therapy. Cancer Medicine, 2015, 4, 1844-1852.	2.8	7
43	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus – Initial Experience Report and Literature Review. Kidney Cancer, 2019, 3, 71-77.	0.4	7
44	Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer. Practical Radiation Oncology, 2019, 9, e528-e533.	2.1	7
45	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure. European Urology Oncology, 2018, 1, 276-282.	5.4	6
46	Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer Journal of Clinical Oncology, 2021, 39, 311-311.	1.6	5
47	Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanioa€™s Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569 (19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead	3.1	3
48	or printj-European Grology Focus, 2021, 7, 401–105. Enrichment of "Cribriform―morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer. Modern Pathology, 0, , .	5.5	3
49	Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer Journal of Clinical Oncology, 2021, 39, 4564-4564.	1.6	2
50	Safety and outcome of stereotactic body radiation therapy (SBRT) with rectal hydrogel spacer for prostate cancer Journal of Clinical Oncology, 2020, 38, 76-76.	1.6	2
51	Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation. International Journal of Radiation Oncology Biology Physics, 2020, 108, 914-916.	0.8	1
52	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study Journal of Clinical Oncology, 2018, 36, 586-586.	1.6	1
53	Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): A phase II randomized controlled trial of stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer Journal of Clinical Oncology. 2020. 38. TPS381-TPS381.	1.6	1
54	The combination of radiation therapy and immunotherapy for genitourinary cancer treatment: rationale, current evidence, and prospects. Journal of Radiation Oncology, 2015, 4, 355-363.	0.7	0

#	Article	IF	CITATIONS
55	The effects of anticoagulant use in high-risk prostate cancer treated with radiotherapy on overall survival and biochemical control Journal of Clinical Oncology, 2014, 32, 146-146.	1.6	0
56	Improved survival rates in kidney cancer patients with brain metastases treated with modern multidisciplinary approaches Journal of Clinical Oncology, 2018, 36, 601-601.	1.6	0
57	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
58	DC-HIL/Gpnmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR) Journal of Clinical Oncology, 2019, 37, e14129-e14129.	1.6	0
59	A real-world experience of immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2020, 38, 647-647.	1.6	Ο
60	Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer Journal of Clinical Oncology, 2022, 40, 245-245.	1.6	0
61	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. Frontiers in Oncology, 2022, 12, 779182.	2.8	0